Filters: author is Danhof [Clear All Filters]
- 2009
Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors,
Eur J Pain, vol. 13, no. 5, pp. 448-57. DOI
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling,
Drug Discov Today, vol. 14, no. 5-6, pp. 316-20. DOI
Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?",
J Ethnopharmacol, vol. 121, no. 3, pp. 479-81. DOI
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography,
Epilepsia, vol. 50, no. 1, pp. 88-98. DOI
Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex,
Anesthesiology, vol. 110, no. 1, pp. 95-105. DOI
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients,
Ther Drug Monit, vol. 31, no. 2, pp. 187-97. DOI
Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera,
Antimicrob Agents Chemother, vol. 53, no. 4, pp. 1574-80. DOI
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling,
Drug Metab Pharmacokinet, vol. 24, no. 1, pp. 3-15. DOI
- 2008
Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model,
J Psychiatr Res, vol. 42, no. 14, pp. 1189-97. DOI
Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy,
J Psychiatr Res, vol. 42, no. 12, pp. 1000-9. DOI
The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments,
J Pharmacol Toxicol Methods, vol. 57, no. 2, pp. 114-30. DOI
Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex,
Eur J Pharm Sci, vol. 33, no. 3, pp. 217-29. DOI
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients,
Clin Pharmacol Ther, vol. 83, no. 3, pp. 443-51. DOI
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42. DOI
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats,
Br J Pharmacol, vol. 153, no. 5, pp. 1072-84. DOI
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients,
Eur J Clin Pharmacol, vol. 64, no. 3, pp. 329-34. DOI
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics,
Eur J Pharm Sci, vol. 34, no. 2-3, pp. 149-63. DOI
Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex,
Br J Pharmacol, vol. 154, no. 6, pp. 1369-78. DOI
Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes,
Am J Obstet Gynecol, vol. 198, no. 1, pp. 108 e1-6. DOI
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats,
Pharm Res, vol. 25, no. 1, pp. 183-93. DOI
Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain,
Br J Pharmacol, vol. 155, no. 7, pp. 1127-38. DOI
The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women,
Br J Clin Pharmacol, vol. 66, no. 6, pp. 866-74. DOI


